Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-26, Stock:ABBV, The news for the past five days is as follows:
2018-06-19: NEWS1: Agree To Purchase AbbVie At $55, Earn 3.2% Using Options.NEWS2: Agree To Purchase AbbVie At $55, Earn 3.2% Using Options.NEWS3: 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities".NEWS4: Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress.NEWS5: 3 Great Reasons to Buy Gilead Sciences.NEWS6: Bristol-Myers Posts Data on Empliciti, China Approves Opdivo.NEWS7: Bristol-Myers Posts Data on Empliciti, China Approves Opdivo.
2018-06-20: NEWS1: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS2: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS3: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS4: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS5: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS6: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.
2018-06-21: NEWS1: ABBV Dividend Yield Pushes Past 4%.NEWS2: ABBV Dividend Yield Pushes Past 4%.NEWS3: XLV, ABBV, AMGN, MDT: ETF Outflow Alert.NEWS4: XLV, ABBV, AMGN, MDT: ETF Outflow Alert.NEWS5: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street.NEWS6: Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities.
2018-06-22: NEWS1: Is AbbVie Inc (NYSE:ABBV) A Buy At Its Current PE Ratio?.NEWS2: Top Research Reports for Procter & Gamble, AbbVie & IBM.
2018-06-25: NEWS1: Monday 6/25 Insider Buying Report: DOVA, ABBV.NEWS2: Monday 6/25 Insider Buying Report: DOVA, ABBV.NEWS3: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric.NEWS4: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric.NEWS5: IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer.NEWS6: The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald&apos;s and General Electric.NEWS7: AbbVie and Calibr announce collaboration for next generation T-cell therapies.

Answer: Decrease